Andrew W. Hahn, MD
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
2015 | The University of Tennessee Health Science Center, Memphis, TN, USA, MD, Medicine |
2011 | The University of Tennessee at Knoxville, Knoxville, TN, USA, BA, Integrated Study of Synthetic Medicinal Chemistry |
Board Certifications
2018 | ABIM-Internal Medicine |
Honors & Awards
2022 | Waun Ki Hong Award for Achievement in Clinical Investigation |
2022 | Harold C. and Mary L. Dailey Endowed Fellowship |
2021 | Selected participant in 2021 AACR/ASCO Virtual Methods in Clinical Cancer Research Workshop, AACR/ASCO |
2021 | Conquer Cancer Young Investigator Award, PCF |
2021 | Selected participant in the MD Anderson Cancer Center “Leading Clinical Research Faculty Course”, MD Anderson Cancer Center |
2021 | Conquer Cancer Merit Award |
2019 | Conquer Cancer Foundation Merit Award, ASCO |
2019 | Susan Cooper Jones Endowed Fellowship in Cancer Research |
2018 | ESMO Annual Meeting Best Poster Award, Genitourinary/Prostate, ESMO |
2017 | Conquer Cancer Foundation ASCO Merit Award, ASCO |
2015 | UTHSC Achievement in Research Award, UTHSC |
2015 | American College of Physicians (ACP) Young Achiever Award, ACP |
2014 | Member of Alpha Omega Alpha |
2014 | The Herman Bensdorf Merit Scholarship |
2012 | The Billy and Sally Gore Medical Student Memorial Fund Scholarship |
2012 | NIH Summer Research Fellowship at St. Jude Children’s Research Hospital, NIH |
2012 | Member of Phi Beta Kappa Honor Society |
Selected Publications
Peer-Reviewed Articles
- Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, Négrier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barthélémy P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Asim Bilen M, Choueiri TK, Albiges L, Tannir NM, Malouf GG. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. Oncologist 27(12):1041-1047, 2022. e-Pub 2022. PMID: 35979929.
- Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res 19(3):395-402, 2021. e-Pub 2020. PMID: 33323389.
- Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open 5(6):e001073, 2020. PMID: 33229506.
- Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 78(5):652-656, 2020. e-Pub 2020. PMID: 32624276.
- Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N. Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. J Geriatr Oncol 11(4):724-726, 2020. e-Pub 2019. PMID: 31402176.
- Agarwal N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks J, Santos VS, Nachaegari G, Wang X, Boucher K, Haaland B, Maughan BL. Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res 26(9):2104-2110, 2020. e-Pub 2020. PMID: 31937614.
- Moses M, Niu A, Lilly MB, Hahn AW, Nussenzveig R, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J, Agarwal N, Sartor O, Barata PC. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun 24:100193, 2020. e-Pub 2020. PMID: 32702615.
- Boyle JL, Hahn AW, Kapron AL, Kohlmann W, Greenberg SE, Parnell TJ, Teerlink CC, Maughan BL, Feng BJ, Cannon-Albright L, Agarwal N, Cooney KA. Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer. JCO Precis Oncol 4, 2020. e-Pub 2020. PMID: 32923906.
- Hahn AW, Klaassen Z, Agarwal N, Haaland B, Esther J, Ye XY, Wang X, Pal SK, Wallis CJD. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2(6):708-715, 2019. e-Pub 2019. PMID: 31588018.
- Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urol Oncol 37(6):352.e19-352.e24, 2019. e-Pub 2019. PMID: 30770300.
- Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer 125(9):1459-1469, 2019. e-Pub 2019. PMID: 30620391.
- Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol 20(4):581-590, 2019. e-Pub 2019. PMID: 30827746.
- Hahn AW, Gill DM, Poole A, Nussenzveig RH, Wilson S, Farnham JM, Stephenson RA, Cannon-Albright LA, Maughan BL, Agarwal N. Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). Mol Cancer Ther 18(3):726-729, 2019. e-Pub 2018. PMID: 30587554.
- Hale P, Hahn AW, Rathi N, Pal SK, Haaland B, Agarwal N. Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. J Geriatr Oncol 10(1):149-154, 2019. e-Pub 2018. PMID: 29861146.
- Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houldsworth J, Pal SK, Agarwal N. Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS One 14(1):e0210415, 2019. e-Pub 2019. PMID: 30682039.
- Hahn AW, Stenehjem D, Nussenzveig R, Carroll E, Bailey E, Batten J, Maughan BL, Agarwal N. Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. Cancer Treat Res Commun 19:100120, 2019. e-Pub 2019. PMID: 30743187.
- Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N. Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clin Genitourin Cancer. e-Pub 2017. PMID: 28958675.
- Agarwal N, Hahn AW, Gill DM, Farnham JM, Poole AI, Cannon-Albright L. Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer. JAMA Oncol 3(6):856-857, 2017. PMID: 28208175.
- Patel DA, Hahn AW, Martin MG. 9p24 abnormalities in hematologic malignancies with a focus on diffuse large B-cell lymphoma. Med Oncol 34(5):95, 2017. e-Pub 2017. PMID: 28409436.
- Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal N. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget 8(20):33614-33620, 2017. PMID: 28431395.
- Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urol 17(1):1, 2017. e-Pub 2017. PMID: 28056941.
- Hahn AW, Giri S, Pathak R, Bhatt VR, Martin MG. Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract. Anticancer Res 36(8):4051-5, 2016. PMID: 27466512.
- Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N. Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience 10:676, 2016. e-Pub 2016. PMID: 27729941.
- Hahn AW, Martin MG. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol 16(16):e580-1, 2015. PMID: 26678198.
Invited Articles
- Hahn AW, George DJ, Agarwal N. An Evolving Role for AXL in Metastatic Renal Cell Carcinoma. Clin Cancer Res 27(24):6619-6621, 2021. e-Pub 2021. PMID: 34598944.
- Hahn AW, Msaouel P, Tannir NM. Lenvatinib plus pembrolizumab as first-line therapy for patients with advanced or metastatic, treatment-naïve, clear cell renal cell carcinoma (RCC): is it the best immuno-oncology doublet in RCC?. ASCO Post, 2021.
- Hahn AW, Agarwal N. The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas. Cancer Treat Res Commun 24:100190, 2020. e-Pub 2020. PMID: 32679555.
- Hahn AW, Sirohi D, Agarwal N. The Role of PD-L1 Testing in Advanced Genitourinary Malignancies. Eur Urol Focus 6(1):11-13, 2020. e-Pub 2019. PMID: 30872123.
- Esther J, Hale P, Hahn AW, Agarwal N, Maughan BL. Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. Drugs Aging 36(5):395-401, 2019. PMID: 30784023.
- Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Curr Treat Options Oncol 20(2):14, 2019. e-Pub 2019. PMID: 30741354.
- Hahn AW, Tannir NM. Targeting glutamine metabolism: the CANTATA trial for patients with metastatic renal cell carcinoma. Kidney Cancer Journal, 2019.
- Hahn AW, Nussenzveig RH, Maughan BL, Agarwal N. Cell-free circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): current knowledge and potential uses. Kidney Cancer, 2019.
- Bergerot PG, Hahn AW, Bergerot CD, Jones J, Pal SK. The Role of Circulating Tumor DNA in Renal Cell Carcinoma. Curr Treat Options Oncol 19(2):10, 2018. e-Pub 2018. PMID: 29464405.
- Gill DM, Hahn AW, Hale P, Maughan BL. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Curr Treat Options Oncol 19(1):6, 2018. e-Pub 2018. PMID: 29368125.
- Hahn AW, Gill DM, Agarwal N, Maughan BL. PD-1 checkpoint inhibition: Toxicities and management. Urol Oncol 35(12):701-707, 2017. e-Pub 2017. PMID: 28889921.
- Hahn AW, Hale P, Rathi N, Agarwal N. Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. Curr Opin Urol 27(6):559-565, 2017. PMID: 28816716.
- Hahn AW, Gill DM, Pal SK, Agarwal N. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy 9(8):681-692, 2017. PMID: 28653573.
- Gill D, Hahn AW, Sonpavde G, Agarwal N. Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Hum Vaccin Immunother 12(12):2997-3004, 2016. e-Pub 2016. PMID: 27494417.
- Hahn AW, Li B, Prouet P, Giri S, Pathak R, Martin MG. Acute megakaryocytic leukemia: What have we learned. Blood Rev 30(1):49-53, 2016. e-Pub 2015. PMID: 26228843.
- Hahn AW, Jamy O, Nunnery S, Yaghmour G, Giri S, Pathak R, Martin MG. How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(11):646-54, 2015. e-Pub 2015. PMID: 26386907.
Other Articles
- Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs 39(5):1405-1410, 2021. PMID: 33770291.
- Rathi N, Anderson N, Greenberg S, Vagher J, Agarwal N, Hahn AW DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC). World J Oncol 9(4):119-122, 2018. PMID: 30220950.
- Bowen RC, Hahn AW, Butler TW, Khong HT Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy. Mol Clin Oncol 6(1):122-124, 2017. PMID: 28123744.
- Hahn AW, Giri S, Patel D, Sluder H, Vanderwalde A, Martin MG Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis. J Natl Compr Canc Netw 13(10):1181-5, 2015. PMID: 26483058.
Editorials
- Hahn AW, Bilen MA, Agarwal N. Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement. JAMA Netw Open 4(1):e2034652, 2021. PMID: 33496790.
- Hahn AW, Pal SK, Agarwal N. Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome. Oncologist 24(2):143-145, 2019. PMID: 30139834.
- Hahn AW, Pal SK, Agarwal N. Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. The Oncologist, 2019. PMID: 31615950.
- Hahn AW, Pal SK, Agarwal N. HSD3B1-A Predictive Biomarker in Advanced Prostate Cancer. JAMA Oncol 4(4):562-563, 2018. PMID: 29049481.
- Hahn AW, Nussenzveig RH, Pal SK, Agarwal N. Blood- and tissue-based tumor genomics: a battle royale or match made in heaven?. Ann Oncol 28(10):2333-2335, 2017. PMID: 28945831.
- Shuch B, Hahn AW, Agarwal N. Current Treatment Landscape of Advanced Papillary Renal Cancer. J Clin Oncol 35(26):2981-2983, 2017. PMID: 28737973.
Book Chapters
- Westaby D, Viscuse PV, Ravilla R, de la Maza MLDF,Hahn AW, Sharp A, de Bono J, Aparicio A, Fleming MT. Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. In: Am Soc Clin Oncol Educ Book, e190-e202, 2021.
- Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N. Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. In: Am Soc Clin Oncol Educ Book, 363-371, 2018.
- Hahn AW, Karam JA, Wood CG, Tannir NM. Renal Carcinoma. In: The MD Anderson Manual of Medical Oncology. 4th. McGraw Hill.
Grant & Contract Support
Title: | The impact of body composition on resistance to androgen signaling inhibition (ASI) in men with localized high-risk prostate cancer |
Funding Source: | Prostate Cancer Foundation |
Role: | Principal Investigator |
Title: | Adiposity, Nuclear Hormone Signaling, and the Response Phenotype to Androgen Signaling Inhibition in Metastatic Prostate Cancer |
Funding Source: | Department of Defense (DOD) |
Role: | Principal Investigator |
Title: | The impact of interactions between adiposity and androgen signaling inhibition on outcomes in men with metastatic prostate cancer |
Funding Source: | Conquer Cancer Foundation |
Role: | Principal Investigator |
Patient Reviews
CV information above last modified June 07, 2024